UPDATED Jun 27, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
BOVN.F | SEK 4.70 | 0% | n/a | SEK 2.7b | SEK 12.58 | PS9.2x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
0RV2 | SEK 221.40 | 1.1% | -20.5% | SEK 19.5b | SEK 368.67 | PS77.4x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
SGEN | US$228.74 | 4.5% | 76.5% | US$43.2b | US$228.91 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IMGN | US$31.23 | 6.6% | 617.9% | US$8.4b | US$28.95 | PS29.1x | E45.8% | n/a | Pharmaceuticals & Biotech | ||
0A8R | US$228.95 | 4.6% | 81.1% | US$43.2b | US$229.12 | PS18.8x | E71.8% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$1.20 | -8.4% | 6.2% | US$144.4m | US$9.23 | PB0.8x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
0A8K | US$31.24 | 6.4% | 658.3% | US$8.4b | US$29.16 | PS29.1x | E45.9% | n/a | Pharmaceuticals & Biotech | ||
ARDX | US$6.50 | 10.4% | 95.2% | US$1.4b | US$13.83 | PS9.6x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
BRCT.F | SEK 21.20 | 1.0% | -29.4% | SEK 19.5b | SEK 34.98 | PS78.1x | E50.9% | 0% | Pharmaceuticals & Biotech | ||
LEGN | US$44.66 | 9.5% | -36.4% | US$8.2b | US$82.50 | PS23.7x | E63.7% | n/a | Pharmaceuticals & Biotech | ||
ISEE | US$39.95 | 0.9% | 236.3% | US$5.5b | US$40.00 | PB11.6x | E59.0% | n/a | Pharmaceuticals & Biotech | ||
CSPH.F | HK$0.12 | 0% | n/a | HK$1.5b | n/a | PS3x | E98.1% | n/a | Pharmaceuticals & Biotech | ||
MSB | AU$0.98 | -7.5% | -12.8% | AU$1.1b | AU$1.11 | PS99.8x | E56.7% | n/a | Pharmaceuticals & Biotech | ||
TVTX | US$8.28 | 19.1% | -45.9% | US$628.1m | US$14.86 | PS4x | E67.6% | n/a | Pharmaceuticals & Biotech | ||
IVBI.Y | HK$19.68 | -0.4% | n/a | HK$63.6b | HK$27.99 | PS9.5x | E50.8% | n/a | Pharmaceuticals & Biotech | ||
0JDK | US$8.05 | 0.3% | 14.7% | US$2.3b | US$25.87 | PS1177.2x | E64.5% | n/a | Pharmaceuticals & Biotech | ||
SPRY | US$8.05 | 4.1% | 21.8% | US$782.9m | US$19.00 | PS78000.7x | E58.7% | n/a | Pharmaceuticals & Biotech | ||
RCEL | US$7.95 | -4.2% | -54.5% | US$206.3m | US$23.22 | PS4.1x | E61.3% | n/a | Pharmaceuticals & Biotech | ||
ALDX | US$3.40 | 0.1% | -57.0% | US$193.1m | US$9.25 | PB1.8x | E60.0% | n/a | Pharmaceuticals & Biotech | ||
MGTX | US$4.23 | -1.9% | -36.1% | US$270.7m | US$21.20 | PS23.9x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
CLRB | US$2.33 | -16.8% | 25.9% | US$103.6m | US$15.25 | PB9.2x | E66.9% | n/a | Pharmaceuticals & Biotech | ||
MDGL | US$285.66 | 6.7% | 29.7% | US$5.9b | US$365.07 | PB7.2x | E64.3% | n/a | Pharmaceuticals & Biotech | ||
ACAD | US$16.37 | 11.0% | -31.8% | US$2.6b | US$27.35 | PS3.3x | E41.5% | n/a | Pharmaceuticals & Biotech | ||
SLNO | US$41.75 | 2.4% | 894.0% | US$1.4b | US$67.29 | PB10.6x | E65.2% | n/a | Pharmaceuticals & Biotech |